The short version of the Tavneos dispute
- Amgen requested a formal hearing with the U.S. Food and Drug Administration (FDA) on July 23, 2026, to contest the proposed removal of Tavneos (avacopan) from the market.
- The FDA cited 76 cases of serious liver injury and 8 deaths linked to the drug as of March 2026.
- Europe’s drug regulator (EMA) recommended revoking the drug’s approval in June 2026, labeling the original study data as unreliable.
- Amgen submitted real-world data from more than 70 studies involving over 2,200 patients to support the drug’s continued availability.
- The final deadline for Amgen to provide all supporting analyses to the FDA is July 29, 2026.
The numbers behind the Tavneos dispute
| Metric | Value Reported |
|---|---|
| Drug Name | Tavneos (avacopan) |
| Primary Indication | ANCA-associated vasculitis (AAV) |
| Liver Injury Cases | 76 serious cases (8 deaths) |
| Real-World Evidence Base | 70+ studies (2,200+ patients) |
| U.S. Patient Population | 15,000 to 20,000 |
| Filing Deadline | July 29, 2026 |
Amgen battles to keep vasculitis treatment on market
Amgen is currently engaged in a high-stakes regulatory defense of its drug Tavneos (avacopan) as the U.S. Food and Drug Administration (FDA) moves toward a potential market withdrawal. On July 23, 2026, the biotechnology company filed a request for a formal hearing and submitted a significant volume of new data. This move follows an FDA proposal from April 2026 to pull the drug, which was originally approved in 2021 for the treatment of a rare and dangerous autoimmune condition.
The dispute centers on whether the benefits of the drug outweigh newly identified risks. While the drug remains available to patients for now, its future depends on the FDA Commissioner’s final order. An FDA official confirmed that the company has until July 29, 2026, to deliver its full package of data and analysis to support the request for a hearing.
Understanding ANCA-associated vasculitis and avacopan
To understand the conflict, one must look at the disease the drug treats. ANCA-associated vasculitis (AAV) is a rare autoimmune disorder where the body produces antibodies that mistakenly attack small blood vessels. This attack leads to severe inflammation that can shut down organs (most notably the kidneys and lungs). Standard treatment usually involves high doses of steroids, which often cause severe side effects over long periods.
Tavneos was marketed as a breakthrough because it works differently. It targets the complement system, a part of the immune response that acts like a chemical alarm system. Specifically, the drug blocks the C5a receptor (C5aR) on white blood cells. By quieting this receptor, the drug prevents the “alarm” from calling in the inflammatory cells that damage blood vessels. This mechanism was designed to reduce the need for heavy steroid use.
Why the regulatory decision matters
The stakes are high for both the company and the patient community. If the drug is removed, that revenue stream disappears. For the 15,000 to 20,000 patients in the U.S. living with AAV, the withdrawal could mean losing an oral alternative to systemic steroids.
However, the safety signals are grave. In March 2026, the FDA highlighted 76 cases of serious liver injury, including 8 deaths. Some patients developed a rare condition known as vanishing bile-duct syndrome (VBD), which can cause permanent liver damage. The European Medicines Agency (EMA) has already taken a hard stance, recommending in June 2026 that the drug’s approval be revoked. The EMA based this on the conclusion that the original trial data used to get the drug approved was not reliable.
Reading the data with the right caution
It is important to look closely at what the recent reviews actually found compared to the original claims. When Amgen commissioned the Duke Clinical Research Institute (DCRI) to re-examine the original trial data, the results were mixed. The DCRI review confirmed that Tavneos was as effective as standard steroid treatments at the 26-week and 52-week marks.
But there is a catch. The review could not confirm the original claim that Tavneos was “superior” to steroids at 52 weeks. This means the drug may not actually work better than existing, cheaper treatments, even as it introduces new safety risks. Amgen is now leaning heavily on real-world evidence from over 2,200 patients to prove that the drug is safe and effective in everyday clinical use, rather than just in a controlled trial setting.
Sources:
- Medical Dialogues, “Amgen Seeks FDA Hearing, Files New Data to Prevent Tavneos Market Withdrawal” (https://medicaldialogues.in/amp/news/industry/pharma/amgen-seeks-fda-hearing-files-new-data-to-prevent-tavneos-market-withdrawal-175752)
- U.S. Food and Drug Administration, “FDA Identifies Cases of Serious Liver Injury in Patients Taking Tavneos (avacopan)” (https://www.fda.gov/drugs/drug-safety-communications/fda-identifies-cases-serious-liver-injury-patients-taking-tavneos-avacopan-severe-active-anti)
- pharmaphorum, “FDA points to liver injury with Amgen’s Tavneos” (https://pharmaphorum.com/news/fda-points-liver-injury-amgens-tavneos)
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.